Company News: Bristol-Myers Squibb, Mead Johnson and Covidien

Share this article:
Bristol-Myers Squibb said it will split off nutritional business Mead Johnson through a share exchange offer to its stockholders. BMS currently has an 83.1% stake in Mead Johnson—equivalent to 170 million shares. The company said the cashless transaction gives it more room to fund future growth, particularly around biotech drugs.
 
Covidien, which owns marketing rights to experimental pain drug Exalgo, said the drug's developer is in discussions with FDA staff regarding a pending application. According to Covidien, the agency told Exalgo developer Neuromed that its NDA was not sufficient to form the basis for approval. The FDA will complete its review of the opioid drug on November 22. Covidien, whose Mallinckrodt unit obtained the US commercial rights to Exalgo in June, is working with Neuromed to determine next steps.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters